Bahl & Gaynor Inc. Boosts Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Bahl & Gaynor Inc. increased its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2.1% in the second quarter, Holdings Channel.com reports. The firm owned 128,472 shares of the medical instruments supplier’s stock after acquiring an additional 2,595 shares during the period. Bahl & Gaynor Inc.’s holdings in LeMaitre Vascular were worth $10,571,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. YHB Investment Advisors Inc. bought a new stake in LeMaitre Vascular in the first quarter worth $36,000. GAMMA Investing LLC increased its holdings in shares of LeMaitre Vascular by 57.0% in the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after buying an additional 199 shares during the period. West Oak Capital LLC purchased a new position in shares of LeMaitre Vascular in the second quarter worth about $58,000. nVerses Capital LLC lifted its stake in shares of LeMaitre Vascular by 33.3% in the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after acquiring an additional 200 shares during the last quarter. Finally, Van ECK Associates Corp purchased a new stake in LeMaitre Vascular during the 2nd quarter valued at about $75,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Insider Activity

In related news, CEO George W. Lemaitre sold 27,030 shares of the company’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $86.27, for a total value of $2,331,878.10. Following the sale, the chief executive officer now directly owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,030 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the completion of the transaction, the chief executive officer now owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the transaction, the director now owns 14,114 shares of the company’s stock, valued at $1,158,335.98. The disclosure for this sale can be found here. Insiders sold a total of 43,251 shares of company stock worth $3,714,994 in the last quarter. 10.79% of the stock is owned by company insiders.

LeMaitre Vascular Trading Up 0.5 %

Shares of LeMaitre Vascular stock opened at $86.75 on Thursday. LeMaitre Vascular, Inc. has a 12-month low of $44.27 and a 12-month high of $92.90. The company has a market cap of $1.95 billion, a P/E ratio of 57.45, a PEG ratio of 2.32 and a beta of 0.88. The company’s fifty day simple moving average is $86.03 and its two-hundred day simple moving average is $76.96.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The firm had revenue of $55.85 million for the quarter, compared to analyst estimates of $54.98 million. During the same quarter in the previous year, the firm posted $0.37 EPS. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. Analysts predict that LeMaitre Vascular, Inc. will post 1.85 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th were given a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.74%. The ex-dividend date of this dividend was Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

Analyst Ratings Changes

LMAT has been the topic of a number of analyst reports. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday, August 27th. Lake Street Capital assumed coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They set a “buy” rating and a $105.00 price target for the company. Roth Capital raised shares of LeMaitre Vascular to a “strong-buy” rating in a research report on Friday, May 31st. Barrington Research boosted their price objective on shares of LeMaitre Vascular from $79.00 to $92.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Finally, JMP Securities increased their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $94.40.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.